Literature DB >> 28722178

CDK9: A key player in cancer and other diseases.

Lia Carolina Franco1,2, Fátima Morales2,3, Silvia Boffo2, Antonio Giordano2,4.   

Abstract

Cyclin-Dependent Kinase 9 (CDK9) is part of a functional diverse group of enzymes responsible for cell cycle control and progression. It associates mainly with Cyclin T1 and forms the Positive Transcription Elongation Factor b (p-TEFb) complex responsible for regulation of transcription elongation and mRNA maturation. Recent studies have highlighted the importance of CDK9 in many relevant pathologic processes, like cancer, cardiovascular diseases, and viral replication. Herein we provide an overview of the different pathways in which CDK9 is directly and indirectly involved.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CDK9; cancer pathway; cyclin; drug targeting; kinase; transcription regulation; viral replication

Mesh:

Substances:

Year:  2017        PMID: 28722178     DOI: 10.1002/jcb.26293

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  33 in total

1.  Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.

Authors:  Devon R Blake; Angelina V Vaseva; Richard G Hodge; McKenzie P Kline; Thomas S K Gilbert; Vikas Tyagi; Daowei Huang; Gabrielle C Whiten; Jacob E Larson; Xiaodong Wang; Kenneth H Pearce; Laura E Herring; Lee M Graves; Stephen V Frye; Michael J Emanuele; Adrienne D Cox; Channing J Der
Journal:  Sci Signal       Date:  2019-07-16       Impact factor: 8.192

2.  Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9.

Authors:  Qi Jia; Zhiqiang Hu; Nannan Song; Weike Mao
Journal:  Cardiovasc Drugs Ther       Date:  2022-01-28       Impact factor: 3.727

3.  Reversible phosphorylation of cyclin T1 promotes assembly and stability of P-TEFb.

Authors:  Fang Huang; Trang Tt Nguyen; Ignacia Echeverria; Ramachandran Rakesh; Daniele C Cary; Hana Paculova; Andrej Sali; Arthur Weiss; Boris Matija Peterlin; Koh Fujinaga
Journal:  Elife       Date:  2021-11-25       Impact factor: 8.140

4.  From Autonomy to Integration, From Integration to Dynamically Balanced Integrated Co-existence: Non-aging as the Third Stage of Development.

Authors:  Lev Salnikov; Mamuka G Baramiya
Journal:  Front Aging       Date:  2021-03-25

Review 5.  Targeting cyclin-dependent kinase 9 in cancer therapy.

Authors:  Yi-Li Shen; Yan-Mao Wang; Ya-Xin Zhang; Shen-Jie Ma; Le-He Yang; Cheng-Guang Zhao; Xiao-Ying Huang
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

Review 6.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 7.  Targeting CDK9 for Anti-Cancer Therapeutics.

Authors:  Ranadip Mandal; Sven Becker; Klaus Strebhardt
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

Review 8.  CDK9 keeps RNA polymerase II on track.

Authors:  Sylvain Egloff
Journal:  Cell Mol Life Sci       Date:  2021-06-19       Impact factor: 9.261

Review 9.  From cancer to rejuvenation: incomplete regeneration as the missing link (part II: rejuvenation circle).

Authors:  Mamuka G Baramiya; Eugene Baranov; Irina Saburina; Lev Salnikov
Journal:  Future Sci OA       Date:  2020-06-30

10.  ASF1B promotes cervical cancer progression through stabilization of CDK9.

Authors:  Xinjian Liu; Jingwei Song; Yenan Zhang; Huiquan Wang; Hongzhi Sun; Xiaomin Feng; Min Hou; Guo Chen; Qi Tang; Minjun Ji
Journal:  Cell Death Dis       Date:  2020-08-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.